Axiom Clarinet to support NIMBL

07 March 2011
Axiom Clarinet to support NIMBL a major European rare disease research project

We are pleased to announce that Certus has been contracted as a supplier of software and development services to the NIMBL project, a rare disease research project funded by the European Commission's FP7 programme.

The Axiom Clarinet platform is a web based system with features to support form-based data collection coordinated through a workflow management system. The system creates projects. These can be patient or family-centric, or could centre on a gene or a specific in-vivo model. All data and activity within the system is stored in relation to these projects. The system provides a timeline perspective on each project, in a manner similar to a Gantt chart. Workflows allow the system's users to cooperate in the completion of processes such as diagnostic pathways or sample movement tracking.

In the NIMBL project Axiom Clarinet will collect a diverse set of structured and semi-structured data. These are stored in a special database known as a triple store which allows advanced queries and analyses, and importantly, using appropriate ontologies, data linking to publicly available bioinformatic resources.
Nuclease Immune Mediated Brain and Lupus-like (NIMBL) conditions
NIMBL conditions, including Aicardi-Goutieres Syndrome, Retinal Vasculopathy with Cerebral Leukodystrophy and some cases of Systemic Lupus Erythematosus, are genetic disorders that reduce quality of life and have a high mortality especially in children.

The NIMBL project brings together clinical and basic scientists at the forefront of NIMBL-related research to develop a translational approach to these problems. With support from Certus, the Axiom Clarinet platform will form a knowledgebase of patient and research data to help reveal the natural history of the NIMBL diseases and the efficacy of current treatments.

The investigation of NIMBL diseases will ultimately improve the health and well-being of NIMBL patients and their families. It will also lead to better treatments of much more common autoimmune disorders including lupus.